Corient Capital Partners, LLC Astrazeneca PLC Transaction History
Corient Capital Partners, LLC
- $1.34 Billion
- Q3 2022
A detailed history of Corient Capital Partners, LLC transactions in Astrazeneca PLC stock. As of the latest transaction made, Corient Capital Partners, LLC holds 13,966 shares of AZN stock, worth $961,000. This represents 0.07% of its overall portfolio holdings.
Number of Shares
13,966
Previous 11,648
19.9%
Holding current value
$961,000
Previous $770,000
19.87%
% of portfolio
0.07%
Previous 0.06%
Shares
23 transactions
Others Institutions Holding AZN
# of Institutions
1,426Shares Held
504MCall Options Held
10MPut Options Held
3.14M-
Price T Rowe Associates Inc Baltimore, MD57.1MShares$3.93 Billion0.52% of portfolio
-
Primecap Management CO Pasadena, CA40.7MShares$2.8 Billion2.53% of portfolio
-
Wellington Management Group LLP Boston, MA35.6MShares$2.45 Billion0.52% of portfolio
-
Bank Of America Corp Charlotte, NC31.8MShares$2.19 Billion0.19% of portfolio
-
Capital International Investors Los Angeles, CA31.3MShares$2.15 Billion0.47% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $213B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...